CA2480568A1 - Thiazol-2-yl-imine compounds as pde-7 inhibitors - Google Patents

Thiazol-2-yl-imine compounds as pde-7 inhibitors Download PDF

Info

Publication number
CA2480568A1
CA2480568A1 CA002480568A CA2480568A CA2480568A1 CA 2480568 A1 CA2480568 A1 CA 2480568A1 CA 002480568 A CA002480568 A CA 002480568A CA 2480568 A CA2480568 A CA 2480568A CA 2480568 A1 CA2480568 A1 CA 2480568A1
Authority
CA
Canada
Prior art keywords
group
formula
alkyl
compound
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002480568A
Other languages
English (en)
French (fr)
Inventor
Fabrice Vergne
Patrick Bernardelli
Edwige Lorthiois
Pierre Ducrot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2480568A1 publication Critical patent/CA2480568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002480568A 2002-03-28 2003-03-06 Thiazol-2-yl-imine compounds as pde-7 inhibitors Abandoned CA2480568A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02290787.7 2002-03-28
EP02290787A EP1348433A1 (en) 2002-03-28 2002-03-28 Thiazol-2-yl-imine compounds as PDE-7 inhibitors
PCT/EP2003/002276 WO2003082277A1 (en) 2002-03-28 2003-03-06 Thiazol-2-yl-imine compounds as pde-7 inhibitors

Publications (1)

Publication Number Publication Date
CA2480568A1 true CA2480568A1 (en) 2003-10-09

Family

ID=27798933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002480568A Abandoned CA2480568A1 (en) 2002-03-28 2003-03-06 Thiazol-2-yl-imine compounds as pde-7 inhibitors

Country Status (8)

Country Link
US (1) US6852720B2 (enExample)
EP (2) EP1348433A1 (enExample)
JP (1) JP2005528367A (enExample)
AU (1) AU2003215635A1 (enExample)
BR (1) BR0308807A (enExample)
CA (1) CA2480568A1 (enExample)
MX (1) MXPA04009421A (enExample)
WO (1) WO2003082277A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
EP1875915A4 (en) * 2005-04-28 2010-11-17 Dainippon Sumitomo Pharma Co THERAPEUTIC AGENT FOR TREATING CHRONIC OBSTRUCTIVE RESPIRATORY DISEASE
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20230104760A (ko) 2010-11-08 2023-07-10 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
CA3264513A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054669B9 (en) * 1998-02-17 2004-09-15 Boehringer Mannheim Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives
KR100824156B1 (ko) * 2000-06-30 2008-04-21 다이닛본 스미토모 세이야꾸 가부시끼가이샤 5원환 화합물

Also Published As

Publication number Publication date
EP1348433A1 (en) 2003-10-01
WO2003082277A1 (en) 2003-10-09
JP2005528367A (ja) 2005-09-22
BR0308807A (pt) 2005-01-04
AU2003215635A1 (en) 2003-10-13
US20030186988A1 (en) 2003-10-02
US6852720B2 (en) 2005-02-08
EP1492530A1 (en) 2005-01-05
MXPA04009421A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
CA2480679A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
EP2235014B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique.
HUP0100042A2 (hu) Benzofuránkarboxamidok, azokat tartalmazó gyógyszerkészítmények és gyógyászati felhasználásuk
US6852720B2 (en) Thiazol-2-yl-imine compounds as PDE-7 inhibitors
CZ20023934A3 (cs) Deriváty beta-karbolinu pro použití jako inhibitory fosfodiesterázy
US4772606A (en) Purine derivatives
EP2197860B1 (en) New compounds as adenosine a1 receptor antagonists
JP2001506230A (ja) 新規ピペラジン含有化合物
OA12963A (en) Novel chemical compounds.
JP2006503826A (ja) ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
CA2383268A1 (en) Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
NZ312157A (en) 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO2010144513A1 (en) Inhibitors of phosphatidylinositol 3-kinase
JP2007501836A (ja) アミノピロン類及びａｔｍ阻害剤としてのその使用
JP2004501919A (ja) 化学化合物
CA2721434A1 (en) Inhibitors of phosphatidylinositol 3-kinase
NZ328858A (en) 7-(substituted alkylene)-oxy-flavone derivatives and medicaments
EP0178178A2 (en) Purine derivatives
US4952693A (en) Oxazolo-pyrimidine derivatives
KR100588222B1 (ko) 히드록시알킬 인돌로카르바졸 유도체, 제조방법 및 이들을함유하는 약제 조성물
SU1641191A3 (ru) Способ получени 1,3,4-тиадиазол-2-цианамида или его фармацевтически приемлемых солей
JP3805677B2 (ja) 新規な５−ピリミジンカルボキサミド誘導体及び該誘導体を含む製薬組成物
US5051429A (en) "Pyrimidine derivatives"
AU2020471055A1 (en) Pyrimidine- and nitrogen-containing bicyclic compound
HK1083443B (en) Thiazolidin-4-ones for inhibiting hyak3 proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead